ArgusEye AB today announce the appointment of Sofia Håkansson Buch as its new Chief Executive Officer (CEO), marking an important step in the company’s next phase of growth. With a strong background in biopharma, Sofia will lead the company’s continued growth and commercialization of its real-time bioprocess monitoring platform.

Sofia brings extensive experience from the bioprocessing industry, including roles across both biologics and cell therapy, with a focus on process development, manufacturing, and commercialization. Her deep understanding of the challenges and opportunities within bioprocessing will be instrumental as ArgusEye continues to scale its technology and expand its presence in key markets.

“I am excited to step into the role as CEO at ArgusEye and to join the company at such an important stage in its growth journey. Having spent many years in bioprocessing, both within biologics and cell therapy, I know firsthand how critical process insight and control are to ensure quality, efficiency, and faster development times. In our industry, you need to truly have ‘eyes on the process’ to succeed. ArgusEye has developed a powerful technology platform that addresses exactly this need. By enabling deeper understanding and real-time insight into bioprocesses, we have the opportunity to help the industry develop competitive products faster. I look forward to working together with our talented team, partners, and  customers  to  scale  the  company  and  to  bring  this  impactful  technology  to  a broader global market,” says Sofia Håkansson Buch.

As part of this transition, Erik Martinsson, co-founder of ArgusEye and current CEO, will assume the role of Chief Technology Officer (CTO), where he will focus on further advancing the company’s technology and product development.

“Founding and leading ArgusEye as CEO has been an incredibly rewarding journey, and I am very proud of the progress we have made in bringing our sensor technology to the market. Together with an exceptional team, we have built a strong foundation and a technology  that  can truly make a difference  in bioprocessing. In my new role as CTO, I am excited to return to a stronger focus on technology and innovation, and to support the company’s continued growth in its next phase,” says Erik Martinsson.

Torben Jørgensen, Chairman of the Board comments:

“We are pleased to welcome Sofia as the new CEO of ArgusEye at this important stage in the company’s development and commercialization. Her strong industry experience and deep understanding of bioprocessing will be invaluable as we continue to scale the company and bring our technology to a broader market.

At the same time, I want to thank Erik for his strong commitment to the company, and we are  grateful  for his leadership  in  founding  and  building  ArgusEye  into  the  company  it  is today. His transition to CTO ensures continued focus on innovation and technological excellence, which remain at the core of our strategy.

With this new leadership team in place, we are confident that ArgusEye is well positioned to accelerate its growth and deliver significant value to our customers and stakeholders.”

About ArgusEye

ArgusEye delivers  advanced sensor solutions  for real-time bioprocess  monitoring  and  control, supported by more than 40 years of research and a team of experts based in Linköping, Sweden.

The LSPR biosensing technology enables real-time monitoring of critical quality attributes (CQAs) and critical process parameters (CPPs), giving biopharma companies unprecedented insights and control over their processes. ArgusEye supports continuous, automated workflows that accelerate development, enhance quality, and boost efficiency in bioprocessing.